Showing results (71-80 of 155) with videos related to
Sort By:
Pageof 16
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 28, 2018
c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid CarcinomasXavier Mignard, Anne-Marie Ruppert, Martine Antoine, et al.European Journal of Cancer (Oxford, England : 1990)|December 20, 2015
Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patientsFrédéric Fiteni, Dewi Vernerey, Franck Bonnetain, et al.Lung Cancer (Amsterdam, Netherlands)|March 10, 2015
Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational studyDenis Moro-Sibilot, Egbert Smit, Javier de Castro Carpeño, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2013
Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancerStéphane Vignot, Garrett M Frampton, Jean-Charles Soria, et al.Journal of Geriatric Oncology|February 21, 2015
Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301)Gaetan Des Guetz, Thierry Landre, Virginie Westeel, et al.International Journal of Cancer|March 9, 2022
A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT-0701 MAPS phase 3 trialElodie Maille, Jérôme Levallet, Fatéméh Dubois, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 5, 2021
Prospective Multicenter Validation of the Detection of ALK Rearrangements of Circulating Tumor Cells for Noninvasive Longitudinal Management of Patients With Advanced NSCLCMarius Ilié, Julien Mazières, Emmanuel Chamorey, et al.Translational Oncology|September 6, 2025
MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trialGuénaëlle Levallet, Christian Creveuil, Alexandre Léger-Vigot, et al.The European Respiratory Journal|October 28, 2017
Association between lung cancer somatic mutations and occupational exposure in never-smokersChristophe Paris, Pascal Do, Bénédicte Mastroianni, et al.Oncotarget|December 30, 2017
Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitorsSimon Baldacci, Julien Mazieres, Pascale Tomasini, et al.Pageof 16